Exhibit 99.1
  Press Release

    Investor Relations/
  Media Contact:   Janet M. Barth
      (908) 879-2428
Success of new product introductions and competitive in-market performance of
Mucinex®and Delsym® drove Adams’ retail consumption to grow more than $130 million,
an increase of nearly 70 percent over fiscal 2006
Financial Highlights
  Fiscal 2007 fourth quarter net sales of $46.9 million declined 11 percent from net sales of $52.8 million in the prior year period. Despite the lower reported net sales growth, Adams’ retail consumption increased 44 percent during the fiscal 2007 fourth quarter, according to Information Resources Inc. (IRI) data for the 52 weeks ended July 1, 2007. Net sales in the fiscal 2006 fourth quarter benefited from $11.0 million in sales related to the reduction in the product backorder that was generated in the first half of fiscal 2006.
  Net sales in fiscal 2007 increased 39 percent to $331.6 million, in line with Adam’s previously disclosed annual net sales guidance range of $320 to $335 million. This growth was driven by Adams’ retail consumption that grew more than $130 million, an increase of nearly 70 percent over fiscal 2006, according to IRI data.
  Income per diluted share of $0.82 for fiscal 2007 includes pretax charges of $14.9 million (or $0.26 per diluted share), comprised of $9.7 million related to the repurchase of the Ft. Worth, Texas manufacturing operations in July 2006; a $2.7 million non-cash charge related to the AlleRx™ royalty interest recorded in December 2006; and a $2.5 million non-cash charge related to the impairment of the Humibid® intangible asset in June 2007.
Other Highlights
  The Food and Drug Administration (FDA) announced its intention to take enforcement action to remove all unapproved timed-release guaifenesin products from the market, including prescription versions of Adams’ Mucinex DM and Mucinex D. (May)
  Adams’ dollar share of the total cough/cold/allergy/sinus (CCAS) category increased nearly 4 market share points to 10.4 percent, from 6.6 percent in the prior year period, according to IRI data for the 52 weeks ended July 1, 2007, compared to the prior year period.
  Adams’ portfolio expansion is underway with strong initial trade shipments of the new Mucinex products, including Maximum-Strength Mucinex, Mucinex Nasal Sprays and new items in the Mucinex for Children product line. (August)
CHESTER, N.J. (Aug. 21, 2007) – Adams Respiratory Therapeutics, Inc. (NASDAQ: ARxT) today announced financial results for the fourth quarter and fiscal year ended June 30, 2007.


The following information was filed by Adams Respiratory Therapeutics, Inc. on Tuesday, August 21, 2007 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Adams Respiratory Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adams Respiratory Therapeutics, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account